Αποτελέσματα Αναζήτησης
Table 1 Statin Dosing and ACC/AHA Classification of Intensity. From ACC/AHA, 2018. 199 Dosages shown are total daily dosages; exceptions are noted. Abbreviations: ACC=American College of Cardiology; AHA=American Heart Association; LDL-C=low-density lipoprotein cholesterol; NA=not applicable. From: Chapter 1, Introduction and Background.
14 Σεπ 2021 · This article reviews the evidence and guidelines for using high-intensity statins to lower LDL-C levels and prevent ASCVD events in high-risk patients. It also discusses the challenges and strategies for improving statin adherence and tolerance.
1 Ιουλ 2023 · Learn how statins are classified into low, moderate, or high intensity based on how much they lower LDL cholesterol. Find out why high-intensity statin therapy may be recommended for people with coronary artery disease.
17 Μαρ 2019 · If in the context of a risk discussion, maximal ASCVD risk reduction is desired, it is reasonable to use a high-intensity statin to lower LDL-C by ≥50%. This provides increased benefit, especially when 10-year ASCVD risk is ≥20%.
This document provides evidence-based recommendations for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD) with statins and other lipid-lowering therapies. It covers the measurement, goals, and monitoring of LDL-C and non-HDL-C, as well as the use of PCSK9 inhibitors and ezetimibe.
High-intensity statins are recommended for 2 categories of pa-tients: those with ASCVD (secondary prevention) and high-risk patients without clinical ASCVD. Most patients with ASCVD are candidates for high-intensity statins, with a goal for low-density li-poprotein cholesterol reduction of 50% or greater.
31 Οκτ 2018 · Among patients achieving treatment target for LDL ‐C after percutaneous coronary intervention, high‐intensity statins were associated with a lower risk of major adverse cardiovascular events than non‐high‐intensity statins despite a small difference in achieved LDL ‐C level.
